Two-thirds of sports medicine physicians surveyed report using at least one orthobiologic. [1] The clinical evidence for PRP, shockwave, and biologics continues to grow.
Orthopedic Product Suite
These are the service lines orthopedic practices evaluate most often when considering regenerative medicine. Each comes with device support, clinical education, and ongoing technical support. All included with your partnership.
Also available for your practice:
Clinical Evidence
Orthopedic providers don't adopt therapies based on marketing. They adopt based on published data, institutional positioning, and what holds up in peer review. Here's where regenerative orthobiologics stand.
The published literature on PRP injection in knee osteoarthritis settings now includes 18 RCTs and 1,995 patients. [2] That's a substantial body of peer-reviewed data.
AAOS acknowledged that orthobiologics show 'great promise' for less invasive treatment of certain musculoskeletal conditions, while recommending continued research. [3] Not a blanket endorsement. But recognition that the evidence base warrants serious clinical consideration.
The evidence informs the conversation. Your clinical judgment determines how these therapies are applied.
Revenue Potential
Regenerative therapies collect at time of service. No insurance billing, no prior authorization, no reimbursement delays. Here's what the published data says about practice-level economics.
66%
of sports medicine physicians surveyed report using at least one orthobiologic [1]
Key Metrics
Shockwave runs on a single device with minimal consumable costs per session. [4] PRP adds a second revenue layer with strong per-procedure margins at low preparation costs. Both collect at time of service, independent of your insurance mix.
Revenue varies by utilization, geography, and practice type. The figures above reflect published data, not projections of individual performance.
Common Questions
Important Disclosures
Device disclaimer
PRP preparation devices and shockwave therapy devices distributed by Luci Medical are FDA-cleared Class II medical devices. Clinical applications are determined by the treating provider's clinical judgment. Uses beyond the device's cleared indications are not cleared by FDA. Clinical application decisions rest with the treating provider. Luci Medical provides published clinical literature to support informed decision-making.
Revenue disclaimer
Individual results vary based on utilization, geography, and practice type. Revenue figures on this page reflect published third-party data and are not guarantees or projections of individual practice performance.
Adoption data source
Adoption statistics sourced from AOSSM sports medicine physician survey, PubMed Central, 2021. Luci Medical makes no claim regarding current industry-wide adoption rates.
You've seen the evidence and the economics. Let's talk about whether it fits your practice.
